Company Update (NYSE:MRK): Data on Vericiguat, Investigational Heart Failure Medicine, to be Presented as Late-Breaking Clinical Trial at the 2015 American Heart Association (AHA) Scientific Sessions

[PR Newswire] – WHIPPANY, N.J. and KENILWORTH, N.J., Nov. 6, 2015 /PRNewswire/ — Bayer and Merck (MRK), known as MSD outside the United States and Canada, announced today that new data on vericiguat . . . → Read More: Company Update (NYSE:MRK): Data on Vericiguat, Investigational Heart Failure Medicine, to be Presented as Late-Breaking Clinical Trial at the 2015 American Heart Association (AHA) Scientific Sessions Similar Articles: Stock Update (NYSE:MRK): Data in Nine Difficult-to-Treat Cancers from Merck’s KEYTRUDA® (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: … Market Update: Merck & Co Inc (NYSE:MRK) – Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015 Company Update: Merck & Co Inc (NYSE:MRK) – 2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck’s Rapidly Expanding Immuno-Oncology Research Program for KEYTRUDA® (pembrolizumab) to be Presented